Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 30; p. v494
Main Authors	Conter, H.J., MacDonald, L.D., Fiset, S., Bramhecha, Y.M., Chaney, M., Rosu, G.N.
Format	Journal Article
Language	English
Published	01.10.2019
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534
DOI:	10.1093/annonc/mdz253.034